Nanocapsule-mediated sustained H release in the gut ameliorates metabolic dysfunction-associated fatty liver disease.
Jin Z, Sun Y, Yang T, Tan L, Lv P, Xu Q, Tao G, Qin S, Lu X, He Q · Biomaterials · 2021
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
The publication “Nanocapsule-mediated sustained H release in the gut ameliorates metabolic dysfunction-associated fatty liver disease.” is organized in H2HUBB under the research focus molecular hydrogen fatty liver study 2021 jin. The publication is cited as Jin Z, Sun Y, Yang T, Tan L, Lv P, Xu Q, Tao G, Qin S, Lu X, He Q, Biomaterials, 2021. This uncontrolled human study examined Nanocapsule-mediated sustained H release in the gut ameliorates metabolic dysfunction-associated fatty liver disease. The abstract describes Human participants. The abstract reports: Moreover, hepatic transcriptome showed a reprogramed liver metabolism profile with reduced lipid synthesis and increased fatty acid metabolism. This is an automated editorial draft based on the abstract and requires source review before publication.
Molecular hydrogen fatty liver study 2021 jin overview
We then investigated its efficacy in treating early-stage MAFLD and other metabolic dysfunctions such as obesity and diabetes. Because this is human clinical evidence, relevance depends on participant selection, controls, sample size, treatment duration, adherence, outcome measures, and replication.
Study design and hydrogen intervention
Publication type: Uncontrolled human study. Evidence type: Human clinical evidence. Research model or population: Human participants. Blinding: Unknown. Control status: Unknown.
Delivery method: Other or not reported.
Reported findings and scientific interpretation
For this molecular hydrogen fatty liver study 2021 jin, the study record reports the following: The abstract reports: Moreover, hepatic transcriptome showed a reprogramed liver metabolism profile with reduced lipid synthesis and increased fatty acid metabolism.
These findings should be interpreted as one piece of evidence rather than as a stand-alone medical conclusion. Results can be influenced by the research model, study design, treatment protocol, sample size, outcome selection, statistical methods, and whether the findings have been independently reproduced.
How this research record was prepared
H2HUBB organizes bibliographic details, study design information, intervention data, outcomes, limitations, and safety notes from the available scientific source. Automated classification supports database organization, but it does not replace critical reading of the complete paper. Source identifiers, evidence labels, and delivery-method fields are retained so readers can verify the record and compare it with related publications. A missing field means the information was unavailable or not reported in the structured source; it should not be treated as a negative finding.
Limitations, safety, and original source
Limitations: The abstract alone may not report all methodological limitations; full-text review is required.
Safety: The hydrogen nanocapsule attenuated both diet-induced and genetic mutation induced early-stage MAFLD, obesity, and diabetes in mice, without any tissue toxicity.
This H2HUBB page is an educational research record, not medical advice. Review the original scientific source for the complete methods and results. Continue exploring the H2HUBB Molecular Hydrogen Research Library to compare evidence types, delivery methods, and related topics.